ONKURE THERAPEUTICS, INC. Stock-Based Compensation
ONKURE THERAPEUTICS, INC. (OKUR) reported Stock-Based Compensation of $5.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-04
- ONKURE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.05M, a 4.85% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.78M, a 1.28% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.02M, a 19.19% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.96M, a 3745.45% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $11.63M, a 156.80% increase from fiscal 2024.
- ONKURE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $4.53M, a 2176.38% increase from fiscal 2023.
- ONKURE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $199.00K, a 95.39% decline from fiscal 2022.
- ONKURE THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $4.32M, a 11.03% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $5.83M 10-Q · filed 2026-08-04 | $8.85M derived: sum of 3 quarters · filed 2026-08-04 | $11.81M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $2.78M 10-Q · filed 2026-05-05 | $5.80M derived: sum of 2 quarters · filed 2026-05-05 | $8.76M derived: sum of 3 quarters · filed 2026-05-05 | $11.67M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.98M derived: sum of 2 quarters · filed 2026-03-12 | $8.89M derived: sum of 3 quarters · filed 2026-08-04 | $11.63M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $2.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.87M derived: sum of 2 quarters · filed 2026-08-04 | $8.61M 10-Q · filed 2025-11-06 | $11.15M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $2.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $5.65M 10-Q · filed 2026-08-04 | $8.19M derived: sum of 3 quarters · filed 2026-08-04 | $8.26M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $2.75M 10-Q · filed 2026-05-05 | $5.28M derived: sum of 2 quarters · filed 2026-05-05 | $5.36M derived: sum of 3 quarters · filed 2026-05-05 | $7.17M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.61M derived: sum of 2 quarters · filed 2026-03-12 | $4.42M derived: sum of 3 quarters · filed 2026-03-12 | $4.53M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.89M derived: sum of 2 quarters · filed 2025-11-06 | $2.00M 10-Q · filed 2025-11-06 | $2.89M 10-Q · filed 2024-11-07 | -$1.60M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.92M 10-Q · filed 2025-08-12 | $2.07M 10-Q · filed 2024-08-13 | -$1.67M derived: sum of 3 quarters · filed 2025-08-12 | -$245.00K derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | $107.00K 10-Q · filed 2025-05-06 | $1.08M 10-Q · filed 2024-05-07 | -$3.49M derived: sum of 2 quarters · filed 2025-05-06 | -$2.06M derived: sum of 3 quarters · filed 2025-05-06 | -$851.00K derived: sum of 4 quarters · filed 2025-05-06 | |||
| 2023-12-31 | -$3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$2.17M derived: sum of 2 quarters · filed 2025-03-10 | -$958.00K derived: sum of 3 quarters · filed 2025-03-10 | $199.00K 10-K · filed 2025-03-10 | $5.11M 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.64M derived: sum of 2 quarters · filed 2024-11-07 | $3.79M 10-Q · filed 2024-11-07 | $5.01M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.36M 10-Q · filed 2024-08-13 | $3.58M derived: sum of 3 quarters · filed 2024-08-13 | $4.57M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $1.16M 10-Q · filed 2024-05-07 | $2.37M derived: sum of 2 quarters · filed 2024-05-07 | $3.36M derived: sum of 3 quarters · filed 2024-05-07 | $4.37M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $2.21M derived: sum of 2 quarters · filed 2024-03-28 | $3.21M derived: sum of 3 quarters · filed 2024-03-28 | $4.32M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $990.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.00M derived: sum of 2 quarters · filed 2023-11-13 | $3.10M 10-Q · filed 2023-11-13 | $4.52M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.11M 10-Q · filed 2023-08-10 | $3.53M derived: sum of 3 quarters · filed 2023-08-10 | $4.68M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $1.11M 10-Q · filed 2023-05-11 | $2.53M derived: sum of 2 quarters · filed 2023-05-11 | $3.67M derived: sum of 3 quarters · filed 2023-05-11 | $4.53M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $2.57M derived: sum of 2 quarters · filed 2023-03-27 | $3.42M derived: sum of 3 quarters · filed 2023-03-27 | $3.89M 10-K · filed 2023-03-27 | ||||
| 2021-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $2.00M derived: sum of 2 quarters · filed 2022-11-08 | $2.47M 10-Q · filed 2022-11-08 | $2.60M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $854.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.32M 10-Q · filed 2022-08-09 | $1.45M derived: sum of 3 quarters · filed 2022-08-09 | $1.54M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $471.00K 10-Q · filed 2022-05-10 | $600.00K derived: sum of 2 quarters · filed 2022-05-10 | $684.00K derived: sum of 3 quarters · filed 2022-05-10 | $772.00K derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | $129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $213.00K derived: sum of 2 quarters · filed 2022-03-23 | $301.00K derived: sum of 3 quarters · filed 2022-03-23 | $393.00K 10-K · filed 2022-03-23 | ||||
| 2020-09-30 | $84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $172.00K derived: sum of 2 quarters · filed 2021-11-12 | $264.00K 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | $88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $180.00K 10-Q · filed 2021-08-11 | ||||||
| 2020-03-31 | $92.00K 10-Q · filed 2021-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |